Correlation between DNA Methylation and Cell Proliferation Identifies New Candidate Predictive Markers in Meningioma.
Sebastien HergalantChloé SaurelMarion DivouxFabien RechCelso PougetCatherine GodfraindPierre RouyerStéphanie LacommeShyue-Fang Battaglia-HsuGuillaume GauchottePublished in: Cancers (2022)
Meningiomas are the most common primary tumors of the central nervous system. Based on the 2021 WHO classification, they are classified into three grades reflecting recurrence risk and aggressiveness. However, the WHO's histopathological criteria defining these grades are somewhat subjective. Together with reliable immunohistochemical proliferation indices, other molecular markers such as those studied with genome-wide epigenetics promise to revamp the current prognostic classification. In this study, 48 meningiomas of various grades were randomly included and explored for DNA methylation with the Infinium MethylationEPIC microarray over 850k CpG sites. We conducted differential and correlative analyses on grade and several proliferation indices and markers, such as mitotic index and Ki-67 or MCM6 immunohistochemistry. We also set up Cox proportional hazard models for extensive associations between CpG methylation and survival. We identified loci highly correlated with cell growth and a targeted methylation signature of regulatory regions persistently associated with proliferation, grade, and survival. Candidate genes under the control of these regions include SMC4 , ESRRG , PAX6 , DOK7 , VAV2 , OTX1 , and PCDHA - PCDHB - PCDHG , i.e., the protocadherin gene clusters. This study highlights the crucial role played by epigenetic mechanisms in shaping dysregulated cellular proliferation and provides potential biomarkers bearing prognostic and therapeutic value for the clinical management of meningioma.
Keyphrases
- dna methylation
- genome wide
- gene expression
- copy number
- signaling pathway
- cell proliferation
- machine learning
- deep learning
- free survival
- cell cycle
- radiation therapy
- squamous cell carcinoma
- physical activity
- transcription factor
- depressive symptoms
- cerebrospinal fluid
- pi k akt
- optical coherence tomography
- drug delivery
- sleep quality